Registry on HIV-related lymphoma
Characteristics, Treatment and Outcomes of HIV-infected Patients With Malignant Lymphoma: A Registry Study of the European Hematology Association (EHA) Lymphoma Group
This study collects information from people with HIV-related lymphoma to see how they are treated and how well those treatments work.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Rotkreuzklinikum München gGmbH Academic / other |
| Drugs / interventions | cART |
| Locations | 6 sites (Munich, Select One Option and 5 other locations) |
| Trial ID | NCT05231135 on ClinicalTrials.gov |
What this trial studies
This study collects data on patients with HIV-associated lymphoma to analyze their characteristics, treatment approaches, and outcomes. It includes both retrospective and prospective data from individuals diagnosed with non-Hodgkin lymphoma or Hodgkin lymphoma since January 1, 2010. The treatment choices will adhere to established national and international guidelines, and data will be pseudonymized for confidentiality. The central data management is conducted at Red Cross Hospital in Munich, Germany.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have a confirmed diagnosis of HIV and either non-Hodgkin lymphoma or Hodgkin lymphoma.
Not a fit: Patients diagnosed with HIV more than three months after their lymphoma diagnosis may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve understanding of treatment outcomes for patients with HIV-related lymphoma, leading to better management strategies.
How similar studies have performed: Other studies have explored HIV-related lymphomas, but this registry approach may provide novel insights into treatment outcomes in the context of combination antiretroviral therapy.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histology or cytology proven non-Hodgkin lymphoma or Hodgkin lymphoma * HIV-infection at time of lymphoma diagnosis * Lymphoma diagnosis since 01.01.2010 * Adult patients ≥ 18 years * Written informed consent Exclusion Criteria: * HIV-diagnosis \> 3 months after the diagnosis of malignant lymphoma * Non-Compliance or lack of opportunity for follow-up (for the prospective part of the study)
Where this trial is running
Munich, Select One Option and 5 other locations
- Red Cross Hospital Munich — Munich, Select One Option, Germany (Recruiting)
- University Hospital Cologne — Cologne, Germany (Recruiting)
- Amsterdam University Medical Centers — Amsterdam, Netherlands (Not_yet_recruiting)
- Hospital de la Santa Creu i Sant Pau — Barcelona, Spain (Recruiting)
- Hospital Universitario de Salamanca — Salamanca, Spain (Recruiting)
- University Hospital of Wales — Cardiff, United Kingdom (Not_yet_recruiting)
Study contacts
- Study coordinator: Marcus Hentrich, MD
- Email: marcus.hentrich@swmbrk.de
- Phone: +49 89 1303 4372
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.